日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Prospective Observational Case Series in Infertile Women with Overweight or Obesity Treated with a Very-Low Calorie Ketogenic Diet (VLCKD) Prior to an In Vitro Fertilization (IVF) Treatment

一项前瞻性观察病例系列研究,研究对象为超重或肥胖的不孕女性,她们在接受体外受精(IVF)治疗前接受了极低热量生酮饮食(VLCKD)治疗。

Casalechi, Maíra; Piontini, Alessandra; Nicolosi, Annaelisa; Bergomas, Francesca; Napolitano, Filomena; Turolo, Stefano; Reschini, Marco; Riccaboni, Alessandra; Bellinghieri, Roberta; Somigliana, Edgardo; Vigna, Luisella

Immunogenicity and safety of the non-typable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial

一项随机、2a期、非劣效性试验的结果显示,在接种重组带状疱疹疫苗后接种非典型流感嗜血杆菌-卡他莫拉菌(NTHi-Mcat)疫苗与单独接种NTHi-Mcat疫苗相比,其免疫原性和安全性如何:一项随机、2a期、非劣效性试验的结果

Galgani, Ilaria; Põder, Airi; Jõgi, Rain; Anttila, Veli-Jukka; Milleri, Stefano; Borobia, Alberto M; Launay, Odile; Testa, Marco; Casula, Daniela; Grassano, Luca; Tasciotti, Annaelisa; Dozot, Marie; Arora, Ashwani K

Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study

一项II期随机、观察者盲法研究,旨在评估两种不同接种方案下三剂非典型流感嗜血杆菌-卡他莫拉菌(NTHi-Mcat)疫苗的安全性和免疫原性。

Galgani, Ilaria; Annaratone, Margherita; Casula, Daniela; Di Maro, Gennaro; Janssens, Michel; Tasciotti, Annaelisa; Schwarz, Tino; Ferguson, Murdo; Arora, Ashwani Kumar

Long-term immunogenicity and safety of a non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine: 4-year follow-up of a phase 1 multicentre trial

非典型流感嗜血杆菌-卡他莫拉菌疫苗的长期免疫原性和安全性:一项1期多中心试验的4年随访

De Smedt, Philippe; Leroux-Roels, Geert; Vandermeulen, Corinne; Tasciotti, Annaelisa; Di Maro, Gennaro; Dozot, Marie; Casula, Daniela; Annaratone, Margherita; Riccucci, Daniele; Arora, Ashwani Kumar

The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer

肿瘤靶向免疫细胞因子 F16-IL2 与阿霉素联合使用:在晚期实体瘤患者中增加剂量并扩展到转移性乳腺癌患者

Chiara Catania, Michela Maur, Rossana Berardi, Andrea Rocca, Anna Maria Di Giacomo, Gianluca Spitaleri, Cristina Masini, Chiara Pierantoni, Reinerio González-Iglesias, Giulia Zigon, Annaelisa Tasciotti, Leonardo Giovannoni, Valeria Lovato, Giuliano Elia, Hans D Menssen, Dario Neri, Stefano Cascinu,